Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2012-02-13 Regulatory Filings
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
1. German Science Day, Berlin
Regulatory Filings Classification · 85% confidence The document is an independent financial research report titled 'Investment Research' regarding 'mic AG'. It provides a detailed analysis of the company's portfolio, SWOT analysis, valuation models (DCF), and financial projections. It is not a company-issued financial report (like a 10-K or IR) but rather an external analyst report. Since the provided categories do not include 'Analyst Report' or 'Equity Research', and it contains detailed financial analysis and valuation, it is best classified under 'Regulatory Filings' (RNS) as the fallback category for miscellaneous financial documents that do not fit the specific corporate filing definitions. FY 2012
2012-02-13 German
J.P. Morgan Healthcare Conference 2012 San Francisco, USA
Investor Presentation Classification · 98% confidence The document is titled "30th Annual J.P. Morgan Healthcare Conference" and is dated January 12, 2012. It contains detailed slides covering the company's pipeline, technology platform, financial guidance for 2011, balance sheet data, and management team profiles. This format—a presentation deck used to communicate strategy, pipeline progress, and financial highlights to investors at a major industry event—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K or an Earnings Release (ER), but rather a detailed presentation intended for investors.
2012-01-16 English
Fund Information / Factsheet 2011
Fund Information / Factsheet Classification · 99% confidence The document is explicitly titled '# Corporate Factsheet October 2011'. It provides a high-level overview of the company (MorphoSys), its business strategy, technologies, stock information, product pipeline status (clinical phases), and key management/contact details. This structure perfectly matches the definition of a 'Fund Information / Factsheet' (FS), which is described as a brief summary of key company facts, financials, and market info. It is not a comprehensive annual report (10-K), an earnings release (ER), or a management discussion/analysis (MDA), but rather a concise summary document.
2011-12-28 English
Investor Presentation 2011
Investor Presentation Classification · 99% confidence The document is titled "Unternehmensprofil Oktober 2011" (Company Profile October 2011) and provides a comprehensive overview of the company (MorphoSys), its business strategy, technologies (HuCAL), product pipeline (MOR103, MOR202, MOR208), partner activities, and management structure. It includes key financial metrics as of 2010 and stock data as of September 30, 2011. This structure—a detailed, periodic summary of the entire business, strategy, and pipeline, often used for investor relations or general corporate disclosure—most closely aligns with an Investor Presentation (IP) or a general corporate factsheet/profile. Given the depth of pipeline and technology detail, 'Investor Presentation' (IP) is the most appropriate classification, as it serves to inform investors about the company's current state and future prospects, distinct from a formal regulatory filing like a 10-K or an earnings release (ER). It is not a short announcement (RPA/RNS) but the substantive material itself.
2011-12-28 German
Deutsches Eigenkapitalforum Frankfurt
Investor Presentation Classification · 98% confidence The document is a presentation titled 'MorphoSys – Investment Proposition' dated November 22, 2011, originating from the 'Deutsches Eigenkapitalforum'. It contains detailed slides covering the company's pipeline, technology platform, financial guidance (P&L, Balance Sheet), management team, and future outlook. This structure—a detailed presentation designed to convey investment strategy, pipeline progress, and financial health to investors—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a transcript (CT).
2011-11-22 English
9te WestLB Deutschland Konferenz Frankfurt, Deutschland
Investor Presentation Classification · 98% confidence The document is titled 'MorphoSys – Investment Proposition' and contains detailed slides covering the company's technology platform, drug pipeline status (including clinical trial phases), financial performance summaries (P&L, Balance Sheet guidance for 2011), management team profiles, and future event timelines. This structure is characteristic of a formal presentation given to investors, typically at a conference or an investor day. It is not a full regulatory report (like 10-K or IR), nor is it a short announcement of a report (RPA/RNS). Therefore, it best fits the Investor Presentation (IP) category.
2011-11-16 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.